Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
MHRA Approves Deuruxolitinib for Severe Alopecia Areata
MHRA has approved deuruxolitinib for adults with severe alopecia areata, while making clear that safety and effectiveness will remain under review.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
MHRA Highlights Very Rare NAION Risk with Semaglutide
MHRA has updated semaglutide product information to reflect the very rare risk of non-arteritic anterior ischemic optic neuropathy, adding a new safety point for prescribers and patients to watch closely.
PRAC Updates Ixchiq Safety Warnings After Aseptic Meningitis Review
EMA’s PRAC has recommended updated product information for Ixchiq after reviewing aseptic meningitis as a known but newly reframed risk.
FDA Adds Earlier MRI Monitoring for Leqembi Patients
FDA is requiring earlier MRI monitoring for patients taking Leqembi, a move that shows how postmarketing safety findings can quickly reshape real-world risk management.
Industry Alert: Rising Scrutiny Over Proxy Interviews, False Representation, and Intermediary Misconduct in Pharmacovigilance Hiring
A growing wave of scrutiny is falling not only on candidates accused of false representation, but also on the broader network of intermediaries, facilitators, and operators involved in questionable pharmacovigilance hiring routes.
A Missing Safety Warning in a PIL Became a Bigger GPvP Lesson
MHRA’s amitriptyline defect notification is a useful reminder that GPvP findings can show up in patient-facing materials, not just safety databases and SOPs.
Why XEVMPD Knowledge Still Matters for Modern PV Professionals
Product-data competence may not sound glamorous, but EMA’s 2026 XEVMPD training schedule shows it still matters for pharmacovigilance in practice.
Featured Posts
Why E2B(R3) and EVWEB Skills Still Open Doors in 2026
In a year full of AI discussion, EMA’s 2026 training agenda is a useful reminder that strong reporting fundamentals still matter.
Why AI Governance Is Becoming a Differentiator in PV Careers
In regulated environments, knowing how to use AI is helpful. Knowing how to govern it may become even more valuable.
Why EudraVigilance and E2B(R3) Skills Still Matter in 2026
In a year full of AI talk, EMA’s training agenda is a useful reminder that foundational reporting skills like EudraVigilance use and E2B(R3) literacy still matter.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contact us
Email Us
editor@pvwatchdaily.com